Volume | 1,704,070 |
|
|||||
News | (1) | ||||||
Day High | 1.12 | Low High |
|||||
Day Low | 1.06 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Akebia Therapeutics Inc | AKBA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.09 | 1.06 | 1.12 | 1.095 | 1.10 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,191 | 1,704,070 | $ 1.08 | $ 1,844,554 | - | 0.7801 - 2.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:02:58 | formt | 3,234 | $ 1.09 | USD |
Akebia Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
224.03M | 209.37M | - | 194.62M | -51.93M | -0.25 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Akebia Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AKBA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.16 | 1.20 | 1.06 | 1.14 | 2,675,864 | -0.07 | -6.03% |
1 Month | 1.325 | 1.56 | 1.03 | 1.27 | 3,084,750 | -0.235 | -17.74% |
3 Months | 1.58 | 2.48 | 1.03 | 1.64 | 5,218,355 | -0.49 | -31.01% |
6 Months | 1.00 | 2.48 | 0.9515 | 1.58 | 3,435,696 | 0.09 | 9.00% |
1 Year | 1.42 | 2.48 | 0.7801 | 1.44 | 2,580,561 | -0.33 | -23.24% |
3 Years | 3.51 | 4.33 | 0.241 | 1.28 | 3,777,884 | -2.42 | -68.95% |
5 Years | 5.51 | 13.78 | 0.241 | 2.39 | 3,513,011 | -4.42 | -80.22% |
Akebia Therapeutics Description
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. |